AIMS AGEs augment inflammatory responses by activating inflammatory cascade in monocytes, and hence lead to vascular dysfunction. The current study aims to study a plausible role and mechanism of new… Click to show full abstract
AIMS AGEs augment inflammatory responses by activating inflammatory cascade in monocytes, and hence lead to vascular dysfunction. The current study aims to study a plausible role and mechanism of new library of indole-tethered 1,2,3-triazoles 2-13 in AGEs-induced inflammation. MATERIAL AND METHODS Initially, the analogs were synthesized by cycloaddition reaction between prop-2-yn-1-yl-2-(1H-indol-3-yl) acetate (1) and azidoacetophenone (1a). In vitro antiglycation, and metabolic assays were employed to investigate antiglycation and cytotoxicity activities of indole-triazoles. DCFH-DA, Immunostaining, Western blotting, and ELISA techniques were used to study the reactive oxygen species (ROS) and pro-inflammatory mediators levels. KEY FINDINGS Among all the synthesized indole- triazoles, compounds 1-3, 9-11-13, and their precursor molecule 1 were found to be active against AGEs production in in vitro glucose-and methylglyoxal (MGO)-BSA models. Compounds 1-2, and 11-13 were also found to be nontoxic against HEPG2, and THP-1 cells. Our results show that pretreatment of THP-1 monocytes with selected lead compounds 1-2, and 11-13, particularly compounds 12, and 13 reduced glucose-and MGO-derived AGEs-mediated ROS production (P < 0.001), as compared to standards, PDTC, rutin, and quercetin. They also significantly (P < 0.001) suppressed NF-ĸB translocation in THP-1 monocytes. Moreover, compounds 12, and 13 attenuated the AGEs-induced COX-2 protein levels (P < 0.001), and PGE2 production (P < 0.001) in THP-1 monocytes. SIGNIFICANCE Our data revealed that the indole-triazoles 12, and 13 significantly attenuated the AGEs-induced proinflammatory COX-2 levels, and associated PGE2 production by suppressing AGE-ROS-NF-Kβ nexus in THP-1 monocytes. These compounds can thus serve as candidates for further evaluation as treatment to delay early onset of diabetic vascular complications.
               
Click one of the above tabs to view related content.